Track topics on Twitter Track topics that are important to you
This was a prospective, open, non-comparative study to evaluate the safety and efficacy of rhLH (Luveris) administered subcutaneously in follicular development during ovulation induction in 30 Chinese female subjects with hypogonadotropic hypogonadism.
The objective of this study was to assess the safety and efficacy of r hLH (Luveris) administered subcutaneously in follicular development during ovulation induction. This was a prospective, open, non-comparative study to evaluate the safety and efficacy of Luveris administered subcutaneously in follicular development during ovulation induction in 30 Chinese female subjects with hypogonadotropic hypogonadism. The study was organized on an outpatient basis involving a single cycle of treatment. Prior to entry into the study, the diagnosis of hypogonadotropic hypogonadism was confirmed by history, by the presence or absence of specific clinical features and by measuring serum gonadotrophin levels. Once a subject has signed the informed consent form and after satisfying all eligibility criteria, the subject received a combination of daily injection of r hFSH 150 IU plus r hLH 75 IU. After adequate follicular response, ovulation induction was triggered by an injection of 10,000 IU hCG. Luteal phase function was assessed by serum progesterone level determination.
A phase I sub-study to evaluate the pharmacokinetics of single subcutaneous administrations of rhLH was conducted on 24 healthy Chinese female subjects in China. The subjects were randomised into 3 groups. Each group received a single dose of 75 IU, 150 IU and 300 IU of r hLH. Blood samples were collected at predetermined intervals after the injection. Human LH serum levels were measured with the Serono MAIAclone and the in vitro bioassay MA-10. Safety was also assessed by the incidence and severity of adverse events and significant changes in laboratory values.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Peking Union Medical College Hospital
Published on BioPortfolio: 2014-08-27T03:15:18-0400
The primary objective of the Registry of HYpogonadism in MEn (RHYME) is to establish and maintain a large, multi-national prospective registry of male patients who have been diagnosed with...
The purpose of this study is to determine whether one or more fispemifene dose regimens are more effective than placebo in the treatment of hypogonadism in older men.
The purpose of this study is investigating the effect of testosterone treatment on paraoxonase level in male patients with hypogonadotrophic hypogonadism
The purpose of ZA-302 is to determine the effects of Androxal on morning testosterone and reproductive status in younger overweight men with acquired hypogonadotropic hypogonadism (confirm...
The study is designed to answer the following questions: 1. Is hypogonadism a cause for the metabolic syndrome ? 2. What is the effect of testosterone replacement on the metabolic pa...
Cancer and its treatment in childhood and young adulthood can cause hypogonadism, leading to increased risk of long term morbidity and mortality. The aim of this study was to evaluate the risk of pres...
Hypogonadotropic hypogonadism (HH) is a form of hypogonadism which also known as secondary or central hypogonadism. Congenital HH can occur due to defect in gonadotropin releasing hormone (GnRH) neuro...
Men with primary or secondary hypogonadism (HG) prescribed testosterone therapy (TTh) who terminate treatment early might not obtain the benefit of symptom relief.
Congenital hypogonadotropic hypogonadism (CHH) is classified as Kallmann syndrome (KS) with anosmia/hyposmia or normosmic (n)CHH. Here, we investigated the genetic causes and phenotype-genotype correl...
The purpose of this study was to investigate a novel mutation in the luteinizing hormone beta-subunit (LHB) gene in one male patient with hypogonadism due to selective luteinizing hormone (LH) deficie...
Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).
An anabolic steroid that has been used in the treatment of male HYPOGONADISM, delayed puberty in males, and in the treatment of breast neoplasms in women.
A metallic element of atomic number 30 and atomic weight 65.38. It is a necessary trace element in the diet, forming an essential part of many enzymes, and playing an important role in protein synthesis and in cell division. Zinc deficiency is associated with ANEMIA, short stature, HYPOGONADISM, impaired WOUND HEALING, and geophagia. It is known by the symbol Zn.
An autosomal recessive syndrome occurring principally in females, characterized by the presence of reticulated, atrophic, hyperpigmented, telangiectatic cutaneous plaques, often accompanied by juvenile cataracts, saddle nose, congenital bone defects, disturbances in the growth of HAIR; NAILS; and TEETH; and HYPOGONADISM.
Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections.
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...